ASX:LSH

Stock Analysis Report

Executive Summary

Lifespot Health Ltd, together with its subsidiaries, focuses on the development and commercialization of medical diagnostic and monitoring technology solutions in Australia and Germany.

Risk Analysis

Revenue has declined by -68% over the past year

Has less than 1 year of cash runway

Makes less than USD$1m in revenue (A$198K)

Does not have a meaningful market cap (A$2M)

+ 3 more risks


Snowflake Analysis

Adequate balance sheet and overvalued.

Share Price & News

How has Lifespot Health's share price performed over time and what events caused price changes?


Latest Share Price and Events

Stable Share Price: LSH's share price has been volatile over the past 3 months.


Market Performance


7 Day Return

28.6%

LSH

9.2%

AU Healthcare Services

2.0%

AU Market


1 Year Return

-47.1%

LSH

90.5%

AU Healthcare Services

19.8%

AU Market

Return vs Industry: LSH underperformed the Australian Healthcare Services industry which returned 84.9% over the past year.

Return vs Market: LSH underperformed the Australian Market which returned 19.4% over the past year.


Shareholder returns

LSHIndustryMarket
7 Day28.6%9.2%2.0%
30 Day2.9%12.2%3.8%
90 Day-30.8%-13.5%5.8%
1 Year-47.1%-47.1%91.4%90.5%25.2%19.8%
3 Year-90.8%-90.8%121.5%116.8%39.6%20.9%
5 Yearn/a304.4%269.7%61.8%25.3%

Price Volatility Vs. Market

How volatile is Lifespot Health's share price compared to the market and industry in the last 5 years?


Simply Wall St News

Valuation

Is Lifespot Health undervalued compared to its fair value and its price relative to the market?

1.67x

Price to Book (PB) ratio


Share Price vs. Fair Value

Below Fair Value: Insufficient data to calculate LSH's fair value to establish if it is undervalued.

Significantly Below Fair Value: Insufficient data to calculate LSH's fair value to establish if it is undervalued.


Price To Earnings Ratio

PE vs Industry: LSH is unprofitable, so we can't compare its PE Ratio to the Healthcare Services industry average.

PE vs Market: LSH is unprofitable, so we can't compare its PE Ratio to the Australian market.


Price to Earnings Growth Ratio

PEG Ratio: Insufficient data to calculate LSH's PEG Ratio to determine if it is good value.


Price to Book Ratio

PB vs Industry: LSH is good value based on its PB Ratio (1.3x) compared to the AU Healthcare Services industry average (8.4x).


Next Steps

Future Growth

How is Lifespot Health forecast to perform in the next 1 to 3 years based on estimates from 0 analysts?

39.8%

Forecasted Healthcare industry annual growth in earnings


In this section we usually present revenue and earnings growth projections based on the consensus estimates of professional analysts to help investors understand the company’s ability to generate profit. But as Lifespot Health has not provided enough past data and has no analyst forecast, its future earnings cannot be reliably calculated by extrapolating past data or using analyst predictions.

This is quite a rare situation as 97% of companies covered by SimplyWall St do have past financial data.


Next Steps

Past Performance

How has Lifespot Health performed over the past 5 years?

33.1%

Last years earnings growth


Earnings and Revenue History

Quality Earnings: LSH is currently unprofitable.

Growing Profit Margin: LSH is currently unprofitable.


Past Earnings Growth Analysis

Earnings Trend: Insufficient data to determine if LSH's year-on-year earnings growth rate was positive over the past 5 years.

Accelerating Growth: Unable to compare LSH's earnings growth over the past year to its 5-year average as it is currently unprofitable

Earnings vs Industry: LSH is unprofitable, making it difficult to compare its past year earnings growth to the Healthcare Services industry (8%).


Return on Equity

High ROE: LSH has a negative Return on Equity (-100.3%), as it is currently unprofitable.


Return on Assets


Return on Capital Employed


Next Steps

Financial Health

How is Lifespot Health's financial position?


Financial Position Analysis

Short Term Liabilities: LSH's short term assets (A$1.6M) exceed its short term liabilities (A$345.8K).

Long Term Liabilities: LSH has no long term liabilities.


Debt to Equity History and Analysis

Debt Level: LSH is debt free.

Reducing Debt: LSH has not had any debt for past 5 years.


Balance Sheet

Inventory Level: LSH has a low level of unsold assets or inventory.

Debt Coverage by Assets: Insufficient data to determine if LSH's debt is covered by short term assets.


Cash Runway Analysis

For companies that have on average been loss making in the past we assess whether they have at least 1 year of cash runway.

Stable Cash Runway: LSH has less than a year of cash runway based on its current free cash flow.

Forecast Cash Runway: LSH has less than a year of cash runway if free cash flow continues to reduce at historical rates of -28.5% each year


Next Steps

Dividend

What is Lifespot Health's current dividend yield, its reliability and sustainability?


Dividend Yield vs Market

companyn/amarketbottom25%2.3%markettop25%5.4%industryaverage0.7%forecastin3Yearsn/a

Current dividend yield vs market & industry

Notable Dividend: Unable to evaluate LSH's dividend yield against the bottom 25% of dividend payers, as the company has not reported any payouts.

High Dividend: Unable to evaluate LSH's dividend yield against the top 25% of dividend payers, as the company has not reported any payouts.


Stability and Growth of Payments

Stable Dividend: Insufficient data to determine if LSH's dividends per share have been stable in the past.

Growing Dividend: Insufficient data to determine if LSH's dividend payments have been increasing.


Current Payout to Shareholders

Dividend Coverage: Insufficient data to calculate payout ratio to determine if its dividend payments are covered by earnings.


Future Payout to Shareholders

Future Dividend Coverage: No need to calculate the sustainability of LSH's dividend in 3 years as they are not forecast to pay a notable one for the Australian market.


Next Steps

Management

What is the CEO of Lifespot Health's salary, the management and board of directors tenure and is there insider trading?

AU$137k

CEO Compensation


CEO

Stefan Schraps (46yo)

0yrs

Tenure

AU$137,106

Compensation

Mr. Stefan Schraps serves as Chief Executive Officer of Lifespot Health Ltd. Mr. Schraps oversee the establishment and launch of the Australian operations at Lifespot Health Ltd. He serves as Managing Dire ...


CEO Compensation Analysis

Compensation vs Market: Stefan's total compensation ($USD0.00) is below average for companies of similar size in the Australian market ($USD262.68K).

Compensation vs Earnings: Insufficient data to compare Stefan's compensation with company performance.


Insider Trading

Insider Buying: LSH insiders have bought more shares than they have sold in the past 3 months.


Recent Insider Transactions

SellAU$184,91115 Jan 20
Lifespot Capital AG
EntityCompany
Shares5,640,000
Max PriceAU$0.06
BuyAU$5,08728 Nov 19
Rodney Andrew Hannington
EntityIndividual
Role
Chairman of the Board
Independent Non-Executive Chairman
Shares132,267
Max PriceAU$0.038
BuyAU$5,00003 Nov 19
Rodney Andrew Hannington
EntityIndividual
Role
Chairman of the Board
Independent Non-Executive Chairman
Shares100,000
Max PriceAU$0.05
BuyAU$25,83822 Oct 19
Niv Dagan
EntityIndividual
Shares521,800
Max PriceAU$0.05
BuyAU$25,95222 Oct 19
10 Bolivianos Pty Ltd
EntityCompany
Shares520,001
Max PriceAU$0.054
BuyAU$47,62125 Sep 19
Freedom Trader Pty Ltd
EntityCompany
Shares818,014
Max PriceAU$0.058
BuyAU$11,72025 Sep 19
Freedom Trader Pty Ltd
EntityCompany
Shares200,000
Max PriceAU$0.059
BuyAU$28,90825 Sep 19
10 Bolivianos Pty Ltd
EntityCompany
Shares477,592
Max PriceAU$0.061
SellAU$195,58524 Sep 19
Lifespot Capital AG
EntityCompany
Shares2,860,000
Max PriceAU$0.072

Ownership Breakdown

Dilution of Shares: Shareholders have been diluted in the past year, with total shares outstanding growing by 2.7%.


Management Team

  • Stefan Schraps (46yo)

    Chief Executive Officer & Managing Director of BodyTel GmbH

    • Compensation: AU$137.11k
  • Justyn Stedwell

    Company Secretary

    • Tenure: 3.8yrs
    • Compensation: AU$1.00k

Board Members

  • Frank Cannavo

    Non-Executive Director

    • Tenure: 3.8yrs
    • Compensation: AU$49.16k
  • Andreas Empl

    Non-Executive Director

    • Rod Hannington (58yo)

      Independent Non-Executive Chairman

      • Tenure: 1.8yrs
      • Compensation: AU$38.47k

    Company Information

    Lifespot Health Ltd's company bio, employee growth, exchange listings and data sources


    Key Information

    • Name: Lifespot Health Ltd
    • Ticker: LSH
    • Exchange: ASX
    • Founded:
    • Industry: Health Care Technology
    • Sector: Healthcare
    • Market Cap: AU$2.792m
    • Shares outstanding: 77.57m
    • Website: https://www.lifespot-health.com

    Location

    • Lifespot Health Ltd
    • 1B/205-207 Johnston Street
    • Fitzroy
    • Victoria
    • 3065
    • Australia

    Listings

    TickerExchangePrimary SecuritySecurity TypeCountryCurrencyListed on
    LSHASX (Australian Securities Exchange)YesCommon stockAUAUDJan 2017
    LSHCHIA (Chi-X Australia)YesCommon stockAUAUDJan 2017
    L2HDB (Deutsche Boerse AG)YesCommon stockDEEURJan 2017

    Biography

    Lifespot Health Ltd, together with its subsidiaries, focuses on the development and commercialization of medical diagnostic and monitoring technology solutions in Australia and Germany. The company is developing the BodyTel System that integrates multiple sensors for capturing diagnostic information for additional diseases; and Seng-Vital, a digitally integrated cannabis vaporizer. Lifespot Health Ltd is headquartered in Fitzroy, Australia. 


    Company Analysis and Financial Data Status

    All financial data provided by Standard & Poor's Capital IQ.
    DataLast Updated (UTC time)
    Company Analysis2020/01/19 10:48
    End of Day Share Price2020/01/17 00:00
    Earnings2019/06/30
    Annual Earnings2018/12/31


    Unless specified all financial data is based on a yearly period but updated quarterly. This is known as Trailing Twelve Month (TTM) or Last Twelve Month (LTM) Data. Learn more here.